Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 May 17];7(2):s143. Available from: https://skin.dermsquared.com/skin/article/view/2027